Details

Autor(en) / Beteiligte

• Sanchez-Serna, J
• Martinez-Villanueva, M
• Hernández-Vicente, Á
• Asensio-Lopez, M C
• Noguera, J A
• Pascual-Figal, D A

Titel

Galectina-3 as a biomarker of acute kidney injury risk in patients with decompensated heart failure

Ist Teil von

• Revista clínica espanõla (English edition), 2019-08, Vol.219 (6), p.315-319

Erscheinungsjahr

2019

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• INTRODUCTIONIn decompensated heart failure (HF), both acute kidney injury (AKI) and high Galectina-3 (Gal-3) levels have been associated with poorer outcomes. Plasma Gal-3 levels are affected by renal function; however, the potential role of Gal-3 as a predictor of AKI has not been established. METHODSWe measured Gal-3 concentrations at admission for 175 patients hospitalised for HF and recorded the onset of AKI according to the Risk, Injury, Failure, Loss and End-stage kidney disease (RIFLE) analytical criteria. RESULTSDuring hospitalisation, 44 patients (25.1%) developed AKI, although only 14 (8%) corresponded to more advanced stages. These 14 patients had significantly higher Gal-3 levels at admission, which remained a predictor of AKI after the multivariate adjustment by other predictors and by baseline renal function. CONCLUSIONSHigh Gal-3 levels at admission are associated with a higher risk of AKI during hospitalisation for decompensated HF.